secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2022-11-04T23:59:59+00:00
Accession:  0001764013-22-000139
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant unveils next-gen FcRn inhibitor IMVT-1402; Q2 net loss $47.9M
------------------------------------------------------------------------

- IMVT-1402 observed in animal study to have best-in-class IgG reduction with minimal albumin/LDL impact.
- New batoclimab programs: Phase 2b in CIDP (start by end-2022) and Phase 2 in Graves' disease (early 2023).
- Pro forma cash $476M after $70M October 2022 equity offering; cash runway into H2 2025.
- Q2 net loss $47.9M ($0.41/sh) vs $37.7M ($0.35/sh) YoY; R&D expenses rose to $37.7M.
- IMVT-1402 IND submission early 2023, initial data mid-2023; batoclimab MG and TED trials on track.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401322000139/0001764013-22-000139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401322000139/imvt-20221104.htm
  HTML page:      https://secwatch.observer/filing/0001764013-22-000139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer